Evidence map›Paper›PMID 39787298›Full record

ArticleJournal of medicinal chemistry2025

Sulfilimines from a Medicinal Chemist's Perspective: Physicochemical and in Vitro Parameters Relevant for Drug Discovery.

Nathaniel S Greenwood, Zachary W Boyer, Jonathan A Ellman, Christian Gnamm

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Iron-Catalyzed Asymmetric NHAngewandte Chemie (International ed. in English) · 2026
    Article
  2. Article
  3. RapidThe Journal of organic chemistry · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nathaniel S GreenwoodDepartment of Chemistry, Yale University, New Haven, Connecticut 06520, United States.
Zachary W BoyerDepartment of Chemistry, Yale University, New Haven, Connecticut 06520, United States.
Jonathan A EllmanDepartment of Chemistry, Yale University, New Haven, Connecticut 06520, United States.ORCID 0000-0001-9320-5512
Christian GnammBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riß, Germany.ORCID 0000-0001-7392-9513

Funding

Next-generation C-H functionalization methods for organic synthesis and their applications to biological inquiryR35GM122473 · NIGMS · YALE UNIVERSITY · PI JONATHAN A ELLMAN · 2017 to 2026
$7.6M
NIGMS NIH HHS R35 GM122473
6 · The paper itself

Abstract

While sulfoximines are nowadays a well established functional group for medicinal chemistry, the properties of sulfilimines are significantly less well studied, and no sulfilimine has progressed to the clinic to date. In this account, the physicochemical and in vitro properties of sulfilimines are reported and compared to those of sulfoximines and other more traditional functional groups. Furthermore, the impact on the physicochemical and in vitro properties of real drug scaffolds is studied in two series of sulfilimine-containing analogs of imatinib and hNE inhibitors. We show that sulfilimines can be chemically and configurationally stable under physiologically relevant conditions and that they are basic and highly polar and thus are often beneficial for solubility and metabolic stability, although at the cost of reduced permeability. We conclude that

Indexed as

Drug DiscoveryImatinib MesylateIminesSolubilityAnimalsBenzamidesChemistry, PharmaceuticalHumansPiperazinesPyrimidinesBenzamidesImatinib MesylateIminesPiperazinesPyrimidines

Identifiers

PMID39787298
PMCPMC11867876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.